Latest Articles

Renaissance Capital

Macrocure prices IPO well below the range at $10

Macrocure, an Israeli biotech developing white blood cell injections to treat hard to heal wounds, raised $54 million by offering 5.4 million shares (all primary) at $10, well below the range of $13 to $15. Macrocure plans... Read >>

Zacks.com

Calgon Carbon Signs Pact with Goltens for Hyde GUARDIAN - Analyst Blog

Calgon Carbon 's ( CCC ) fully owned subsidiary Hyde Marine, Inc. has entered into an agreement with Netherland Based Goltens Green Technologies to help shipowners avail a chemical free Hyde GUARDIAN Gold Ballast Water Treatment System (BWTS) in... Read >>

Renaissance Capital

Synchrony Financial prices IPO at $23, low end of the range

Synchrony Financial, a spinoff of GE's private label credit card and consumer finance business, raised $2.9 billion by offering 125 million shares at $23, the low end of the range of $23 $26. Synchrony Financial plans to... Read >>

Zacks.com

JPMorgan to Slash Tech Support Jobs Amid Trading Worries - Analyst Blog

In a bid to streamline its technology platform, JPMorgan Chase & Co. ( JPM ) has decided to cut hundreds of technology support jobs in its corporate and investment bank (CIB) division, per a Wall Street Journal report. As... Read >>

Zacks.com

Will Clorox (CLX) Beat Q2 Earnings on Sound Fundamentals? - Analyst Blog

The Clorox Company ( CLX ) will release fourth quarter fiscal 2014 financial results on Aug 1, before the market opens. Last quarter, this consumer products company posted an earnings surprise of approximately 9.26%. Let's see how things are... Read >>

Investor's Business Daily

Merck, J&J, Baxter Provide Healthy Dividend Stream

Drugmakers aim to help people live healthier lives, but they aren't immune to patent losses. Merck ( MRK ), which has recently faced a number of patent expirations, on Tuesday reported Q2 sales that slowed for... Read >>

Motley Fool

Despite Massive Setbacks in China, Qualcomm Still Benefits

Qualcomm isn't a stranger to China. But while the company's done business in the region for decades, lately China hasn't been too kind to Qualcomm. The country is already in the middle of investigating the company for... Read >>

Zacks.com

Regeneron's Eylea Gets FDA Nod for Diabetic Macular Edema - Analyst Blog

Regeneron Pharmaceuticals, Inc. 's ( REGN ) eye drug Eylea received FDA approval for a third indication − the treatment of diabetic macular edema (DME). Eylea is already approved for the treatment of neovascular age related macular degeneration (wet... Read >>

Zacks.com

Will Church & Dwight (CHD) Miss Q2 Earnings on Soft Demand? - Analyst Blog

Church & Dwight Co. Inc. ( CHD ) is slated to report its second quarter 2014 results on Aug 1, 2014. Last quarter, it posted a positive surprise of 1.4%. Let us see how things are developing for this... Read >>

Motley Fool

Toyota Bets Against Tesla With New Hydrogen Car

Toyota's new hydrogen fuel cell vehicle is expected to be called the Mirai. It will go on sale around the world next year. Source Toyota. It's really happening Toyota 's new... Read >>